Contrary to initial concerns, long-term safety data for thrombopoietin receptor agonists has allayed fears of malignant transformation and irreversible bone marrow fibrosis. The increased reticulin fibrosis observed is reversible upon drug discontinuation, offering significant reassurance for long-term prescribing.

Clinicians can reassure myelofibrosis patients that the drop in hemoglobin often seen when starting ruxolitinib does not carry the same negative prognostic weight as anemia caused by the disease itself. This distinction is crucial for managing patient expectations and continuing effective therapy despite initial side effects.

A diagnosis of myelofibrosis without a JAK2, CALR, or MPL mutation should be treated as a red flag, not a final diagnosis. It warrants a deeper investigation for alternative causes, such as MDS/MPN overlap syndromes or secondary fibrosis from other conditions like autoimmune disease or hairy cell leukemia.

Experts are cautious about using ADCs as long-term frontline maintenance therapy in ovarian cancer. Unlike oral PARPs, prolonged administration of these potent chemotherapies could cause cumulative toxicities, especially bone marrow suppression, potentially rendering patients unable to tolerate essential treatments upon relapse.

Unlike neutropenia, which has established management with G-CSF, CIT is often undertreated. This leads to chemotherapy dose reductions that can worsen patient outcomes. Newer TPO receptor agonists are effective, but the problem itself remains an underappreciated gap in oncology practice.

To combat the significant myelosuppression from the standard 28-day venetoclax cycle in AML, many clinicians are adopting a strategy of performing a bone marrow biopsy around day 21 and pausing the drug if blast clearance is achieved to allow for hematologic recovery.

Patients with ITP who fail or are intolerant to one TPO receptor agonist (e.g., eltrombopag) should not be considered a class failure. Switching to another TPO agent is a viable strategy that can induce a response in nearly half of these cases, particularly for intolerance.

To minimize steroid toxicity, a thrombopoietin receptor agonist (TPORA) should be the immediate second-line therapy for ITP patients who fail their initial course of corticosteroids. There is no need to trial multiple other therapies before considering a TPORA.

While rereading pathology reports is always good practice, it provides the most clinical value in cases of suspected ET. These patients are frequently reclassified as having prefibrotic myelofibrosis, a diagnosis that significantly alters patient counseling, prognosis, and long-term management strategies.